8-K: Waystar to Acquire Iodine Software for $1.25 Billion, Expanding AI Healthcare Payments
Merger Announcement
Waystar Holding Corp. announced a definitive agreement to acquire Iodine Software for $1.25 billion in cash and stock, aiming to enhance its AI-powered healthcare payment software and expand its market reach.
Summary
- Waystar Holding Corp. (WAY) has entered into an Agreement and Plan of Merger to acquire Iodine Software Holdings, Inc. (Iodine) for a total enterprise value of $1.25 billion.
- The consideration for the acquisition is approximately $625 million in cash and 16,751,541 shares of Waystar common stock, valued at a Buyer Stock Price of $37.31 per share.
- The merger has received unanimous approval from the boards of directors of both Waystar and Iodine, as well as from Iodine's sole equityholder, Iodine Software Parent, LLC.
- The transaction is expected to close by year-end 2025, subject to customary closing conditions, including regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act.
- Waystar also announced preliminary second quarter 2025 revenue of approximately $271 million, representing about 15% year-over-year growth.
Sentiment
Score: 9
Explanation: The filing announces a significant strategic acquisition with clear financial and operational benefits, including immediate accretion to key margins, future revenue and EPS accretion, substantial synergies, and market expansion. The tone is highly positive, emphasizing AI leadership and market position.
Positives
- The acquisition extends Waystar's AI leadership into clinical intelligence software, unlocking greater value for clients and shareholders.
- Iodine's solutions are expected to expand Waystar's total addressable market by more than 15%.
- The integration of Iodine's clinical data assets with Waystar's data network is anticipated to enhance Waystar AltitudeAI and quickly expand GenAI applications in prior authorizations, claims management, denial prevention, and appeals.
- The combined company is expected to serve 17 of the 20 U.S. News Best Hospitals, deepening relationships with premier health systems.
- Iodine's fully subscription-based revenue model is expected to strengthen Waystar's financial profile.
- Waystar has identified over $15 million in run-rate cost synergies, projected to be realized within the first 18-24 months post-closing.
- The transaction is expected to be immediately accretive to Waystar's gross margin and adjusted EBITDA margin, and accretive to revenue growth and non-GAAP net income per diluted share in 2027.
Risks
- The proposed merger may not be completed in a timely manner or at all.
- Failure to satisfy any of the conditions to the consummation of the merger, including the receipt of certain regulatory approvals, could prevent closing.
- The occurrence of any event, change, or circumstance that could give rise to the termination of the Merger Agreement.
- The announcement of the proposed transaction may affect Waystar's business relationships, operating results, and business generally.
- Unexpected costs, charges, or expenses may result from the proposed merger.
- Other risks described in the risk factors set forth in Waystar's filings with the SEC, including the most recent Annual Report on Form 10-K filed on February 18, 2025.
Future Outlook
The acquisition is expected to accelerate Waystar's ability to transform healthcare payments through its cloud-based software platform, empowering providers with advanced AI capabilities. It is projected to be immediately accretive to Waystar's gross margin and adjusted EBITDA margin, and accretive to revenue growth and non-GAAP net income per diluted share in 2027. Waystar anticipates expanding GenAI applications in prior authorizations, claims management, denial prevention, and appeals by integrating Iodine's clinical data assets.
Management Comments
- Matt Hawkins, CEO of Waystar: "Our mission is to simplify healthcare payments by eradicating unnecessary denied claims, automating manual work, and increasing transparency for providers and patients. We are committed to transforming healthcare through harnessing the power of AI to tackle the most critical challenges in healthcare payments. Welcoming Iodine’s talented team and clinical intelligence platform to Waystar is a terrific next step in achieving our mission."
- William Chan, Co-Founder and CEO of Iodine Software: "We are proud to have built a market-leading AI software company in partnership with Advent, Bain Capital Ventures, and Silversmith Capital Partners, and are thrilled to join Waystar, an organization that shares our deep commitment to modernizing the revenue cycle for providers. From day one, our focus has been helping hospitals and health systems capture the full value of care through transformational AI. As part of Waystar, we are excited to accelerate that mission and amplify the value delivered to healthcare providers."
- Mike Kadyan, Co-Founder and Chairman of Iodine Software: "Our success has been driven by strong partnerships, continuous innovation, and meaningful outcomes. We look forward to delivering even greater outcomes for providers as part of Waystar’s market-leading platform."
- Lauren Young and Carmine Petrone, Managing Directors at Advent: "It has been a privilege to partner alongside the Iodine team as they have built a category-defining AI-powered revenue cycle platform consistently delivering exceptional ROI to its clients. We are excited to build on that foundation together with Waystar to drive even greater impact across healthcare, empowering organizations to optimize their financial performance."
Industry Context
This acquisition highlights the growing trend of leveraging artificial intelligence to streamline and optimize healthcare administrative processes, particularly in payments and revenue cycle management. The focus on preventing denied claims and reducing administrative costs aligns with broader industry efforts to improve efficiency and financial performance for healthcare providers. The integration of clinical intelligence with payment software represents a significant step towards a more holistic, AI-driven approach to healthcare financial operations.
Comparison to Industry Standards
- The combined company is expected to serve 17 of the 20 U.S. News Best Hospitals, indicating a strong market position among premier healthcare providers, which is a significant benchmark in the industry.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors Member | NA | Advent Nominee | Upon Closing Date | Right granted to Advent International, L.P. as part of the acquisition agreement, contingent on maintaining at least 5% beneficial ownership of Waystar Common Stock. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Size Increase | The size of Waystar's Board of Directors will increase from twelve (12) to thirteen (13) directors. | Upon Closing Date | Accommodates the appointment of the Advent Nominee, reflecting Advent's significant post-merger ownership and influence. |
| Stock Transfer Restrictions (Lockup) | Certain equityholders of Iodine (Advent, Iodine CEO, Michael Kadyan affiliates, and other equityholders) will be subject to lockup periods of 18, 12, or 6 months, respectively, on the transfer of Waystar Common Stock received in the merger. | Upon Closing Date | Aims to stabilize the stock price post-merger by limiting immediate selling pressure from new large shareholders. |
| Registration Rights | Advent International, L.P. will gain certain registration rights, including the right to initiate up to two short-form demand registrations and/or shelf take-downs, and piggyback registration rights, 18 months after the Closing Date. | 18 months after Closing Date | Provides Advent with liquidity options for its Waystar shares after the lockup period, facilitating potential future sales. |
Related Party Transactions
- Advent International, L.P., Iodine's largest shareholder, will receive only Waystar shares in the transaction and will have an 18-month lockup period.
- Advent International, L.P. will gain the right to nominate one representative to Waystar's Board of Directors, contingent on maintaining at least 5% beneficial ownership.
- Certain related party contracts and arrangements between Iodine Software and its related parties are to be terminated prior to or at closing, with no further liability to the acquired company.
Stakeholder Impact
- Shareholders: Existing Waystar shareholders will own approximately 92% of the combined company, while Iodine equity holders will own approximately 8%. The transaction is expected to be accretive to Waystar's financial profile, potentially increasing shareholder value.
- Employees: Iodine's talented team and clinical intelligence platform will be welcomed into Waystar, suggesting integration and potential new opportunities within the larger combined entity.
- Customers: The combined entity will offer enhanced AI capabilities and a broader platform, aiming to provide transformational outcomes across the revenue cycle, potentially improving efficiency and financial performance for healthcare providers.
- Creditors: Waystar expects to maintain a strong balance sheet with an estimated adjusted net leverage ratio of approximately 3.5x, indicating a manageable debt level post-acquisition.
Next Steps
- Consummation of the merger, anticipated by year-end 2025, subject to customary closing conditions and regulatory approvals.
- Waystar will share additional information regarding its second quarter 2025 results on July 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 2021-05-19 | Date of the Existing Credit Agreement for Iodine Software Holdings, Inc. |
| 2022-05-09 | Date of the Amended and Restated Limited Liability Company Agreement of Iodine Software Parent, LLC. |
| 2023-12-31 | End of fiscal year for audited consolidated financial statements of Iodine Software. |
| 2024-06-10 | Date of Waystar Holding Corp. Stockholders Agreement and Amended and Restated Registration Rights Agreement. |
| 2024-12-31 | End of fiscal year for audited consolidated financial statements of Iodine Software and period for calculating top customers/suppliers. |
| 2025-02-18 | Date of Waystar's most recent Annual Report on Form 10-K filed with the SEC. |
| 2025-03-18 | Date of the Non-Disclosure Agreement between Waystar, Inc. and Iodine Software Parent, LLC. |
| 2025-03-31 | Balance Sheet Date for unaudited consolidated financial statements of Iodine Software. |
| 2025-04-10 | Date of Amendment No. 1 to the Waystar Holding Corp. Stockholders Agreement. |
| 2025-06-30 | End of fiscal quarter for Waystar's preliminary results and period for calculating top customers/suppliers. |
| 2025-07-21 | Date for determining Buyer Common Stock outstanding (174,238,972 shares) and the measuring period for Buyer Stock Price ($37.31). |
| 2025-07-23 | Date of the Merger Agreement, Stockholder and Lockup Agreement, Amendment No. 2 to Stockholders Agreement, Joinder Agreement to Registration Rights Agreement, and Press Release announcing the transaction. |
| 2025-07-30 | Scheduled date for Waystar to share additional information regarding its second quarter 2025 results. |
| 2025-11-23 | Termination Date for the Merger Agreement if the merger does not close by this date. |
| 2025-12-31 | Anticipated closing date for the transaction (year-end 2025). |
| 2027 | Expected year for the acquisition to be accretive to revenue growth and non-GAAP net income per diluted share. |
Recommendation
strong buyThe acquisition of Iodine Software by Waystar is a highly strategic move that significantly enhances Waystar's AI capabilities and expands its total addressable market. The transaction is structured to be financially accretive to key metrics (gross margin, EBITDA, revenue growth, non-GAAP net income per diluted share) and includes substantial cost synergies. The combined entity's strengthened market position, particularly serving a large portion of top U.S. hospitals, and its focus on high-growth, subscription-based revenue streams, present a compelling investment opportunity. The 50/50 cash/stock funding mix and manageable leverage ratio further support a positive outlook.
Keywords
Healthcare payments, AI software, Merger, Acquisition, Clinical intelligence, Revenue cycle management, Waystar, Iodine Software, Technology, Healthcare IT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.